| Description | DA 3003-2, a selectively potent Cdc25 inhibitor, exhibits antiproliferative activity and holds potential for prostate cancer research. It induces cell cycle arrest at the G2/M phase and increases the expression of P-tyr 15 Cdc2. |
| In vivo | Pentigetide (1 mg ; four times daily)-treated patients showed a statistically significant greater reduction in the frequency (P = .004) and severity (P = .05) of total nasal symptom score (sneezing, nasal congestion, and rhinorrhea) and in the individual nasal symptom scores compared with placebo-treated patients.[1] |
| Synonyms | NSC663285 |
| molecular weight | 321.76 |
| Molecular formula | C15H16ClN3O3 |
| CAS | 383907-47-9 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |